Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

About this update from Champions Oncology, Inc.

Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR) , a leading translational oncology research organization, today announced the appointment of Brian Alexander , MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health , Flagship Pioneering , and Foundation Medicine . His addition supports Champions' strategy to expand the use of clinically relevant data to inform drug discovery and development. Champions is advancing an approach that connects its portfolio of patient-derived tumor models with molecular and clinical datasets to drive more informed decision-making across the drug development lifecycle. This foundation enables the use of advanced analytics and AI to generate deeper insights into disease biology and improve R&D outcomes. Dr. Alexander's appointment reflects the Company's continued investment in this capability and its evolution toward a more connected translational research platform. "Brian brings a unique combination of clinical, scientific, and data-driven leadership experience that aligns closely with where Champions is heading," said Ronnie Morris , Chairman of the Board at Champions Oncology . "As we continue to expand our data capabilities, his perspective will help us better link tumor models with multi-omic and patient data, accelerate discovery, and support more efficient clinical development." "I'm excited to join Champions at an important point in its evolution," said Dr. Alexander . "The ability to connect well characterized tumor models with rich datasets creates a powerful opportunity to deepen our understanding of disease and enable more informed therapeutic development. I look forward to working with the team to advance this approach." Champions Oncology is building an integrated platform centered on PDX models, combining patient-derived tumors with comprehensive molecular and clinical data. This approach enhances its ability to support partners across the oncology R&D continuum, from early discovery through translational development, with a more data-informed and analytically driven strategy. To learn more about how Champions Data Services powers oncology drug discovery, visit: https://www.championsoncology.com/data-ecosystem About Champions Oncology Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative, highest-quality data through proprietary in vivo and ex vivo platforms. Utilizing its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com . Contact: Gavin Cooper - Vice President of Global Marketing [email protected] +1 (518) 488 9062 SOURCE: Champions Oncology, Inc. View the original press release on ACCESS Newswire

View stock analysis, news, and events for Champions Oncology, Inc.